21 U.S.C. § 355d
Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers
United States · Title 21 — FOOD AND DRUGS · Status: effective
Cite this
- Citation
- 21 U.S.C. § 355d, Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/454239
- Permanent ID
ys:prov:454239@1- SHA-256
08b030c39e0a849e5798cbfdb3fcc76c2da9884d1eed38b0afcb1fd7358b0f1f
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
The Secretary shall establish an internal committee within the Food and Drug Administration to carry out the activities as described in sections 355a(f) and 355c(f) of this title. Such internal committee shall include employees of the Food and Drug Administration, with expertise in pediatrics (including representation from the Office of Pediatric Therapeutics), biopharmacology, statistics, chemistry, legal issues, pediatric ethics, neonatology, and the appropriate expertise pertaining to the pediatric product under review, such as expertise in child and adolescent psychiatry or pediatric rare diseases, and other individuals designated by the Secretary.
Legislative history
The public laws that enacted or amended this section. Tallies are for the whole bill as it passed each chamber — often an omnibus covering far more than this provision — not a vote on this section alone.
- Food and Drug Administration Amendments Act of 2007House: 405–7Senate: no recorded tally
- Food and Drug Administration Safety and Innovation ActHouse: no recorded tallySenate: 96–1
- FDA Reauthorization Act of 2017House: no recorded tallySenate: 94–1